Antiplatelet effects of a new sucralfate-coated aspirin formulation

Current Therapeutic Research - Clinical and Experimental

Volumn 59, Issue 11, 1998, Pages 812-817

  Squadrito, Francesco ^a   Lualdi, Paolo ^b   Biffignandi, Paolo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Lisapharma SpA   (Italy)

Author keywords

Aspirin; Dry coated tablets; Platelet hyperaggregation; Sucralfate

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; SUCRALFATE; THROMBOXANE;

ADULT; AGED; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COATING; DRUG EFFECT; DRUG FORMULATION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION;

EID: 0031724351     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(98)85107-2     Document Type: Article

References (14)

1. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-1581.
2. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: A randomized placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649.
3. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. NEJM. 1997;338:847-860.
4. Peto R, Gray R, Collins R, et al. A randomized trial on the effects of prophylactic daily aspirin among male British doctors. BMJ. 1988;296:313-316.
5. Patrono C. Aspirin as an antiplatelet drug. NEJM. 1994;330:1287-1294.
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither, among 17 187 cases of suspected acute myocardial infarction. Lancet. 1988;2:349-360.
7. Berglund U, Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease. Eur Heart J. 1991;12:428-433.
8. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
9. Ridker PM, Hennekens CH, Tofler GH, et al. Anti-platelet effects of 100 mg alternate day oral aspirin: A randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk. 1996;3:209-212.
10. Patrono C, Roth GJ. Aspirin in ischaemic cerebrovascular disease. How strong is the case for a different dosing regimen? Stroke. 1996;27:756-760.
11. Born GV. Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature. 1967;215:1027-1029.
12. Patrono C, Rende G. Platelet activation and inhibition in unstable coronary syndromes. Am J Cardiol. 1997;80:17E-20E.
13. Pox SC, Burgess-Wilson M, Heptinstall S, Mitchell JRA. Platelet aggregation in whole blood determined using the Ultra-Flo 100 whole blood platelet counter. Thromb Haemost. 1982;48:327-329.
14. Maggi L, Torre ML, Giunchedi P, et al. A new drug delivery system for the sequential administration of two different drugs: Sucralfate and NSAIDs. Presented at the Interscience World Conference on Inflammation, Antirheumatics, Analgesics, and Immunomodulators; April 25-27, 1993; Geneva.